PCSK9 inhibition
Meta-analysis of randomised trials confirms PCSK9 inhibitor antibodies cut Lp(a) by an average of 27% (JACC Adv 2025)
Original title: Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials
This meta-analysis and meta-regression pooled randomised controlled trials comparing monoclonal antibody PCSK9 inhibitors against placebo on plasma Lp(a) levels. Across trials, PCSK9 inhibitors reduced Lp(a) by an average of 27% (95% CI -29.8% to -24.1%, P < 0.001), with mean percent change in LDL cholesterol (P = 0.003) and apolipoprotein B (P < 0.002) both associated with the magnitude of treatment effect. Subgroup analyses showed consistent Lp(a) lowering across comparators, agent (evolocumab -29.35% vs. alirocumab -24.50%), and familial hypercholesterolemia status, but a larger effect with shorter treatment duration (12 weeks or less: -32.43% vs. more than 12 weeks: -22.31%, P interaction < 0.01). This is the most comprehensive quantification yet of the Lp(a)-lowering side effect of PCSK9 monoclonal antibodies, relevant when weighing them against dedicated Lp(a)-targeted agents.
Original abstract
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk.
Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials.
Methods: Studies were retrieved comparing the effect of PCSK9i vs placebo on Lp(a) levels. The primary outcome was percent change in Lp(a) levels. Factors associated with the treatment effect were determined by meta-regression analysis. Subgroup analyses were done to explore potential treatment effect differences.
Results: PCSK9i reduced Lp(a) levels on average of -27% (95% CI: -29.8% to -24.1%, P < 0.001). Factors associated with the treatment effect included mean percent change in low-density lipoprotein cholesterol (P = 0.003, beta coefficient 0.34, 95% CI: 0.11-0.57, tau2 = 94.8, R2 = 11.82) and apolipoprotein B (P < 0.002, beta coefficient 0.4, 95% CI: 0.14-0.64, tau2 = 93.68, R2 = 11.86). Subgroup analyses revealed consistent treatment effect amongst comparators vs placebo: -27.69% (95% CI: -30.85% to -24.54%, P < 0.001), vs ezetimibe: -24.0% (95% CI: -29.95% to -18.01%, P < 0.001), type of PCSK9i, evolocumab: -29.35% (95% CI: -33.56% to -25.14%, P < 0.001) vs alirocumab: -24.50% (95% CI: -27.96% to -21.04%, P < 0.001), and presence of familial hypercholesterolemia: -25.63% (95% CI: -31.96% to -19.30%, P < 0.001 vs no familial hypercholesterolemia: -27.22%; 95% CI: -30.34% to -24.09%, P < 0.001). Varying treatment effects were noted in the duration of treatment (12 weeks or shorter: -32.43% [95% CI: -36.63% to -28.23% vs >12 weeks: -22.31%] [95% CI: -25.13% to -19.49%, P < 0.001]), P interaction < 0.01.
Conclusions: PCSK9is reduce Lp(a) levels by an average of 27%. Mean percent change in low-density lipoprotein cholesterol and apolipoprotein B were associated with treatment effect.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.